HighTower Advisors LLC Increases Stock Position in Amgen Inc. $AMGN

HighTower Advisors LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.9% in the 3rd quarter, Holdings Channel reports. The firm owned 789,377 shares of the medical research company’s stock after purchasing an additional 36,897 shares during the period. HighTower Advisors LLC’s holdings in Amgen were worth $222,806,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the business. Brighton Jones LLC raised its stake in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC raised its stake in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares during the last quarter. Angeles Wealth Management LLC grew its position in Amgen by 29.2% in the 2nd quarter. Angeles Wealth Management LLC now owns 1,314 shares of the medical research company’s stock valued at $367,000 after buying an additional 297 shares during the last quarter. Stratos Wealth Partners LTD. increased its stake in Amgen by 11.4% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 28,245 shares of the medical research company’s stock valued at $7,886,000 after buying an additional 2,899 shares during the period. Finally, Nicholson Wealth Management Group LLC lifted its stake in shares of Amgen by 0.6% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock worth $1,652,000 after acquiring an additional 35 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: European Commission approval for Uplinza (amifampridine) for generalized myasthenia gravis expands Amgen’s labelled indications in Europe and supports incremental near-term revenue potential for the product. Amgen wins EC approval for Uplinza in gMG
• Positive Sentiment: Amgen announced an increase to its dividend to $2.52, which boosts yield and signals management confidence in cash flow — typically supportive for a large-cap, dividend-oriented stock. Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
• Positive Sentiment: Unusually large call-option activity (roughly 320,232 calls bought) points to short-term bullish positioning by some investors, which can amplify upside moves in the stock. (No source link provided in feed)
• Neutral Sentiment: Amgen will present at Citi’s 2026 Virtual Oncology Leadership Summit — a standard investor relations event that raises visibility on oncology programs but is not intrinsically catalytic. AMGEN TO PRESENT AT CITI’S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
• Neutral Sentiment: Analyst notes are mixed: Argus reiterated a Buy with a $400 target while Guggenheim reaffirmed a Hold — this provides conflicting signals but keeps the stock in analysts’ focus. Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Industry coverage (CNBC) on pharma’s resetting priorities — pricing, pipelines and patent cliffs — is a sector-level backdrop that could affect sentiment for large-cap drugmakers like Amgen but is not company-specific. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Recent entries on short interest in the data feed appear to be reporting zero shares / NaN changes (likely a reporting glitch) and do not signal a meaningful rise in short positioning. (No link provided)

Insider Activity

In related news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. The trade was a 30.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AMGN. DZ Bank raised their price objective on shares of Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Citigroup raised their target price on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. UBS Group raised their price objective on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday, January 26th. TD Cowen reaffirmed a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Finally, Royal Bank Of Canada upped their price target on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $354.04.

Amgen Price Performance

AMGN stock opened at $369.19 on Friday. The stock has a market capitalization of $198.80 billion, a price-to-earnings ratio of 25.94, a price-to-earnings-growth ratio of 3.78 and a beta of 0.46. The stock’s fifty day simple moving average is $337.47 and its 200-day simple moving average is $313.68. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $385.12. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period last year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. Amgen’s dividend payout ratio is currently 66.90%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.